Overview

Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
- Primary objective of this observational study was to gain insights into the effects of therapy with Spiriva® (tiotropium bromide) 18 microgram on the health-related quality of life and physical functioning in patients with chronic obstructive pulmonary disease (COPD) and demonstrated hyperinflation. - Secondary objective was to obtain safety data regarding adverse events.
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Bromides
Tiotropium Bromide